How to buy Adverum Biotechnologies stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Adverum Biotechnologies stock

Own Adverum Biotechnologies stock in just a few minutes.

Adverum Biotechnologies, Inc is a biotechnology business based in the US. Adverum Biotechnologies shares (ADVM) are listed on the NASDAQ and all prices are listed in US Dollars. Adverum Biotechnologies employs 167 staff and has a market cap (total outstanding shares value) of USD0.00.

How to buy shares in Adverum Biotechnologies

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Adverum Biotechnologies. Find the stock by name or ticker symbol: ADVM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adverum Biotechnologies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Adverum Biotechnologies, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Adverum Biotechnologies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Adverum Biotechnologies share price

Use our graph to track the performance of ADVM stocks over time.

Adverum Biotechnologies shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$8.75 - USD$26.98
50-day moving average USD$10.625
200-day moving average USD$12.0025
Wall St. target priceUSD$24.89
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.046

Buy Adverum Biotechnologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adverum Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adverum Biotechnologies financials

Gross profit TTM USD$-73,309,000
Return on assets TTM -20.9%
Return on equity TTM -38.57%
Profit margin 0%
Book value $4.453
Market capitalisation USD$896.8 million

TTM: trailing 12 months

Shorting Adverum Biotechnologies shares

There are currently 11.4 million Adverum Biotechnologies shares held short by investors – that's known as Adverum Biotechnologies's "short interest". This figure is 11.2% up from 10.2 million last month.

There are a few different ways that this level of interest in shorting Adverum Biotechnologies shares can be evaluated.

Adverum Biotechnologies's "short interest ratio" (SIR)

Adverum Biotechnologies's "short interest ratio" (SIR) is the quantity of Adverum Biotechnologies shares currently shorted divided by the average quantity of Adverum Biotechnologies shares traded daily (recently around 848072.1641791). Adverum Biotechnologies's SIR currently stands at 13.4. In other words for every 100,000 Adverum Biotechnologies shares traded daily on the market, roughly 13400 shares are currently held short.

However Adverum Biotechnologies's short interest can also be evaluated against the total number of Adverum Biotechnologies shares, or, against the total number of tradable Adverum Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adverum Biotechnologies's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Adverum Biotechnologies shares in existence, roughly 120 shares are currently held short) or 0.126% of the tradable shares (for every 100,000 tradable Adverum Biotechnologies shares, roughly 126 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Adverum Biotechnologies.

Find out more about how you can short Adverum Biotechnologies stock.

Adverum Biotechnologies share dividends

We're not expecting Adverum Biotechnologies to pay a dividend over the next 12 months.

Adverum Biotechnologies share price volatility

Over the last 12 months, Adverum Biotechnologies's shares have ranged in value from as little as $8.75 up to $26.98. A popular way to gauge a stock's volatility is its "beta".

ADVM.US volatility(beta: 1.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adverum Biotechnologies's is 1.4573. This would suggest that Adverum Biotechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Adverum Biotechnologies overview

Adverum Biotechnologies, Inc. , a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site